Potential new treatments for cardiovascular disease

Researchers have identified a new mechanism responsible for the buildup of plaque on artery walls

Potential new treatments for cardiovascular diseaseGlycomics researchers at the University of Alberta and CHU Sainte-Justine have reported a discovery that could lead to new treatments for cardiovascular disease. The researchers identified a new mechanism responsible for the buildup of plaque on artery walls, a process known as atherosclerosis. This plaque, made up of fats, cholesterol and other substances, can restrict…

World’s Longest Hockey Game moving cancer research closer to goal

Annual fundraising effort to support clinical trial of precision drug developed at U of A

World’s Longest Hockey Game moving cancer research closer to goalAs 40 local hockey players brave the elements on an outdoor rink just outside Sherwood Park, Alberta for the World’s Longest Hockey Game, they’ll be making a difference in the lives of cancer patients in Edmonton. Over the course of more than 10 days and nights of non-stop shinny, the game, which began on Feb.…

New way identified to track severity and progression of ALS

Researchers hope to move toward earlier diagnosis and effective treatments

New way identified to track severity and progression of ALSUniversity of Alberta researchers have discovered a new method to identify the severity of Lou Gehrig’s disease in patients and track its progression. The U of A team, led by Sanjay Kalra, a professor in the Division of Neurology, has made progress toward an imaging biomarker for white-matter degeneration in the brains of ALS patients. They hope…

FDA approves new cardiovascular drug based on study at U of A

Vericiguat, which was shown to reduce risk of cardiovascular death and heart failure, passes final regulatory hurdle in the United States

FDA approves new cardiovascular drug based on study at U of AThe U.S. Food and Drug Administration has approved the drug vericiguat for use in patients with heart failure. The drug – a first-of-its-kind, once-daily oral treatment for patients with worsening chronic heart failure – was approved in part thanks to the VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical study…

Collaboration key to solving medicine’s thorniest problems

A focus on teamwork and patient needs has led to breakthroughs in the search for cancer therapies, antivirals and safer drugs

Collaboration key to solving medicine’s thorniest problemsKhaled Barakat was stars-truck the first time he met Michael Houghton in 2012. He knew the U of A virologist and director of the Li Ka Shing Applied Virology Institute was renowned for discovering the hepatitis C virus and was likely to win a Nobel Prize (which Houghton eventually did in 2020). Barakat, a PhD in biophysics, landed an…

New treatment for blood cancer developed

U of A research sets the stage for imminent human trials of B-cell lymphoma treatment

New treatment for blood cancer developedScientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published recently in Nature Communications. The University of Alberta research team led by Luc Berthiaume, cell biology professor in the Faculty of Medicine & Dentistry, spent four years working to…

New drug to treat muscular dystrophy based on U of A research

Created using synthetic DNA, viltolarsen is an excellent example of precision medicine

New drug to treat muscular dystrophy based on U of A researchA University of Alberta researcher’s past work has led to a new drug being approved for use in the United States to treat patients suffering from Duchenne muscular dystrophy (DMD). The drug, viltolarsen, was approved for use in Japan earlier this year and passed a significant hurdle in August when the U.S. Food and Drug…

Antiviral drug remdesivir offers second mechanism of attack

Understanding how the conditionally approved COVID-19 drug works is key to improving treatments, says U of A researcher

Antiviral drug remdesivir offers second mechanism of attackResearchers at the University of Alberta have discovered a novel, second mechanism of action by the antiviral drug remdesivir against SARS-CoV-2, according to findings published in the Journal of Biological Chemistry. The research team previously demonstrated how remdesivir inhibits the COVID-19 virus’s polymerase or replication machinery in a test tube. Matthias Götte, chair of medical microbiology and immunology…

National pharmacare will be very expensive and likely unnecessary

National pharmacare will be very expensive and likely unnecessaryAccording to reports, the Trudeau government may unveil a national pharmacare program in Wednesday’s throne speech in Ottawa. The program may be based on last year’s Hoskins’ report, which recommended an expensive top-down Medicare-style approach that would artificially set drugs prices, restrict patient choice and limit private alternatives. Not only would such a program drive…

Multiple factors will influence pricing for COVID-19 vaccine in Canada

Need to supply enough for herd immunity may push down the price per dose, according to U of A expert

Multiple factors will influence pricing for COVID-19 vaccine in CanadaConventional drug costing models are unlikely to apply when it comes to putting a price tag on a vaccine against COVID-19 for Canadians, according to health economist Christopher McCabe. McCabe is with the University of Alberta’s Faculty of Medicine & Dentistry, and also heads Alberta’s Institute of Health Economics. “When you have an infection that…